Company intelligence / Profile preview

Ostentus Therapeutics

Newport Beach, California, United Statesostentustherapeutics.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

OST-01 has demonstrated anti-cancer activity in leukemia, glioblastoma, lung, colorectal, triple negative breast, ovarian, and pancreatic cancers both in vitro and in vivo. The compound targets both leukemic and cancer stem cells by suppressing upregulated "stemness" signaling. Safety has been demonstrated by the lack of toxic and adverse health effects on both normal and cancer mouse models[2][3].

Therapeutic areas: Oncology
Modalities: Natural compoundsplant-derived compoundsphytochemicals
Industry: Biotech

Drug pipeline

2 assets

OST-01

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

City of Hope

Beyond the preview

Go deeper on Ostentus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ostentus Therapeutics.

Explore the full profile